Tamariz, Leonardo, Bast, Elizabeth, Klimas, Nancy et al. · Clinical therapeutics · 2024 · DOI
Quick Summary
This study looked at whether treatments used for ME/CFS could help people with long COVID. Researchers reviewed records from 108 patients who tried different treatments including low-dose naltrexone, amitriptyline, duloxetine, and physical therapy. They found that patients taking low-dose naltrexone were about 5 times more likely to improve compared to those doing physical therapy alone, with improvements in both fatigue and pain.
Why It Matters
This study is important because it suggests that ME/CFS-adapted treatments may be effective for post-COVID-19 condition, which affects millions of patients. For ME/CFS researchers, it provides preliminary evidence that mechanisms and treatments relevant to their disease may apply to a related condition, potentially opening new therapeutic avenues. The finding about low-dose naltrexone is particularly significant given its favorable safety profile and accessibility.
Observed Findings
Low-dose naltrexone was associated with a 5.04-fold increased hazard of symptom improvement compared to physical therapy alone (95% CI 1.22–20.77; P=0.02).
Both fatigue and pain improved in patients taking low-dose naltrexone.
Amitriptyline showed improvement only in fatigue, not pain.
Most patients in the cohort received amitriptyline.
The study included 108 consecutive patients from a post-COVID-19 clinic.
Inferred Conclusions
Treatments adapted from ME/CFS protocols may benefit post-COVID-19 condition patients, suggesting mechanistic overlap between these conditions.
Low-dose naltrexone may be a promising option for post-COVID-19, potentially addressing multiple symptom domains including pain.
Different medications target different symptoms, suggesting symptom-specific treatment strategies may be warranted.
Randomized controlled trials are needed to confirm these preliminary findings and establish mechanisms of action.
Remaining Questions
What is the optimal dose and duration of low-dose naltrexone for post-COVID-19 and ME/CFS patients?
What This Study Does Not Prove
This observational study cannot establish causation—patients choosing naltrexone may have differed in ways that affected outcomes independent of the medication itself. The study does not definitively prove low-dose naltrexone is effective, only that improvement was associated with its use; a randomized controlled trial is needed to confirm efficacy. Results are from a single clinic and may not generalize to all post-COVID-19 or ME/CFS populations.
Tags
Symptom:Cognitive DysfunctionPainFatigue
Phenotype:Long COVID Overlap
Method Flag:Weak Case DefinitionSmall SampleMixed Cohort